Search

Displaying results 4861 - 4870 of 8517 in total
  1. Drug

    Mivorilaner

    go.drugbank.com/drugs/DB21502
    Experimental

    Mivorilaner has a monoisotopic molecular weight of 587.03 Da.

  2. Drug

    Anrikefon

    go.drugbank.com/drugs/DB21529
    Investigational

    Anrikefon has a monoisotopic molecular weight of 703.44 Da.

  3. Drug

    Lefleuganan

    go.drugbank.com/drugs/DB21533
    Experimental

    Lefleuganan has a monoisotopic molecular weight of 1179.78 Da.

  4. Drug

    Orziloben

    go.drugbank.com/drugs/DB21653
    Experimental

    Orziloben has a monoisotopic molecular weight of 222.13 Da.

  5. Drug

    Tegeprotafib

    go.drugbank.com/drugs/DB21665
    Experimental

    Tegeprotafib has a monoisotopic molecular weight of 326.04 Da.

  6. Drug

    Vamagloxistat

    go.drugbank.com/drugs/DB21666
    Experimental

    Vamagloxistat has a monoisotopic molecular weight of 371.11 Da.

  7. Drug

    Milpecitinib

    go.drugbank.com/drugs/DB21676
    Experimental

    Milpecitinib has a monoisotopic molecular weight of 380.13 Da.

  8. Drug

    Claziprotamide

    go.drugbank.com/drugs/DB21687
    Experimental

    Claziprotamide has a monoisotopic molecular weight of 374.13 Da.

  9. Drug

    BMS-955176

    go.drugbank.com/drugs/DB15193
    Investigational

    BMS-955176 is under investigation in clinical trial NCT02415595 (Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults).

  10. Drug

    Naxitamab

    go.drugbank.com/drugs/DB15965
    ApprovedInvestigational

    [A224604] The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015. … [L24929] Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.